Kolexia
Bourget Philippe Pharmacien
Bourget Philippe
Pharmacien
Hôpital Necker Enfants Malades
Paris, France
72 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Drépanocytose Bêta-Thalassémie Thalassémie Adénocarcinome Hémoglobinopathies Mastocytose Mastocytose généralisée Anémie Mucopolysaccharidose de type III

Collaborateurs

Voir plus
Blanche Stéphane
Blanche Stéphane
Hôpital Necker Enfants Malades, Paris, France
Neven Benedicte
Neven Benedicte
Hôpital Necker Enfants Malades, Paris, France
Ribeil Antoine-Jean
Ribeil Antoine-Jean
Hôpital Necker Enfants Malades, Paris, France
Cavazzana Marina
Cavazzana Marina
Hôpital Necker Enfants Malades, Paris, France

Industries

Voir plus
Roche
1 collaboration(s)
Dernière en 2017
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
A dynamical measure of the black hole mass in a quasar 11 billion years ago.
Nature   29 janvier 2024
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Essai Clinique (Bluebird)   08 janvier 2024
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Essai Clinique (Bluebird)   13 octobre 2023
Philippe Bourget - Facebook
Facebook   19 septembre 2022
Philippe Bourget | Le Quotidien du Pharmacien
Le Quotidien du pharmacien   01 septembre 2022
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone marrow transplantation   14 avril 2022
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease: A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
Essai Clinique (Bluebird)   05 avril 2022
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Nature medicine   24 janvier 2022
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Pediatric blood & cancer   24 juillet 2020
Results from the Completed Hgb-205 Trial of Lentiglobin for β-Thalassemia and Lentiglobin for Sickle Cell Disease Gene Therapy
Blood   13 novembre 2019